A recent metanalysis showed that patients with molecular GBM (presence of TERT promoter mutation, EGFR amplification, or chromosome seven gain and ten loss aberrations) had significantly longer OS times when compared to histological GBM (pooled hazard ratio 0.824, [CI: 0.694–0.98], p = 0.03)) and histological grade, age, and surgical extent were significant prognostic factors, with grade 2 molecular GBM showing better OS rates when compared to histological GBM [16]. This evidence concerns the gene EGFR and glioblastoma.